NZ748506A - Aldose reductase inhibitors and methods of use thereof - Google Patents

Aldose reductase inhibitors and methods of use thereof

Info

Publication number
NZ748506A
NZ748506A NZ748506A NZ74850617A NZ748506A NZ 748506 A NZ748506 A NZ 748506A NZ 748506 A NZ748506 A NZ 748506A NZ 74850617 A NZ74850617 A NZ 74850617A NZ 748506 A NZ748506 A NZ 748506A
Authority
NZ
New Zealand
Prior art keywords
treatment
disorders
skin
diabetic
methods
Prior art date
Application number
NZ748506A
Other languages
English (en)
Inventor
Donald Landry
Andrew Wasmuth
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of NZ748506A publication Critical patent/NZ748506A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
NZ748506A 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof NZ748506A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
PCT/US2017/038505 WO2017223179A1 (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ748506A true NZ748506A (en) 2025-07-25

Family

ID=60783884

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ748506A NZ748506A (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof

Country Status (22)

Country Link
US (6) US10150779B2 (enExample)
EP (3) EP4316603A3 (enExample)
JP (4) JP6895464B2 (enExample)
CN (2) CN109310674B (enExample)
AU (3) AU2017281082B2 (enExample)
CA (1) CA3025081A1 (enExample)
DK (2) DK3757107T3 (enExample)
ES (2) ES2836500T3 (enExample)
FI (1) FI3757107T3 (enExample)
HR (2) HRP20231563T1 (enExample)
HU (2) HUE064911T2 (enExample)
IL (3) IL283809B2 (enExample)
LT (2) LT3352754T (enExample)
MX (2) MX391561B (enExample)
NZ (1) NZ748506A (enExample)
PL (1) PL3757107T3 (enExample)
PT (2) PT3757107T (enExample)
RS (1) RS61239B1 (enExample)
SG (2) SG10202012188VA (enExample)
SI (2) SI3757107T1 (enExample)
WO (1) WO2017223179A1 (enExample)
ZA (1) ZA201808506B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
ES2836500T3 (es) * 2016-06-21 2021-06-25 Univ Columbia Inhibidores de aldosa reductasa y métodos de uso de los mismos
IL272246B1 (en) * 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
US20220071880A1 (en) * 2019-02-12 2022-03-10 Applied Therapeutics, Inc. Methods for treating cutaneous aging
BR112021019596A2 (pt) 2019-04-01 2021-11-30 Applied Therapeutics Inc Inibidores de aldose redutase
EP3966320A4 (en) 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
CN120114457A (zh) * 2019-10-08 2025-06-10 应用治疗公司 用于治疗磷酸甘露变位酶2缺乏的醛糖还原酶抑制剂
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
MX2022013658A (es) * 2020-05-01 2023-03-01 Applied Therapeutics Inc Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.
WO2022197487A1 (en) * 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
IL80475A (en) 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
BR9610207A (pt) 1995-08-28 1999-02-02 American Home Prod Acidos fenóxi acéticos como inibidores da aldose redutase e agentes anti-hiperglicêmicos
US6169087B1 (en) * 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
YU71403A (sh) 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
PL373085A1 (en) * 2002-06-14 2005-08-08 Takeda Pharmaceutical Company Limited Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
ES2613700T3 (es) 2010-07-16 2017-05-25 The Trustees Of Columbia University In The City Of New York Inhibidores de la aldosa reductasa y usos de los mismos
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
ES2836500T3 (es) * 2016-06-21 2021-06-25 Univ Columbia Inhibidores de aldosa reductasa y métodos de uso de los mismos
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Also Published As

Publication number Publication date
CN109310674A (zh) 2019-02-05
IL283809B1 (en) 2023-09-01
SG10202012188VA (en) 2021-01-28
AU2021203801B2 (en) 2023-04-06
AU2021203801A1 (en) 2021-07-15
ES2836500T3 (es) 2021-06-25
SG11201810642XA (en) 2019-01-30
MX391561B (es) 2025-03-21
MX2018016122A (es) 2019-08-01
US20180237451A1 (en) 2018-08-23
JP7368419B2 (ja) 2023-10-24
US20190300543A1 (en) 2019-10-03
EP4316603A3 (en) 2024-04-17
DK3352754T3 (da) 2020-12-07
WO2017223179A1 (en) 2017-12-28
AU2017281082B2 (en) 2021-03-18
AU2023204218A1 (en) 2023-07-27
IL283809B2 (en) 2024-01-01
US10870658B2 (en) 2020-12-22
HUE052101T2 (hu) 2021-04-28
IL304979A (en) 2023-10-01
FI3757107T3 (fi) 2023-12-12
LT3757107T (lt) 2023-12-11
EP3352754B1 (en) 2020-09-02
US20210284652A1 (en) 2021-09-16
AU2017281082A1 (en) 2018-12-06
HUE064911T2 (hu) 2024-04-28
IL263631B (en) 2021-07-29
EP3352754A1 (en) 2018-08-01
HK1259379A1 (en) 2019-11-29
JP2019518779A (ja) 2019-07-04
ZA201808506B (en) 2020-05-27
CN109310674B (zh) 2022-07-08
JP2025124733A (ja) 2025-08-26
EP4316603A2 (en) 2024-02-07
PT3757107T (pt) 2023-12-14
HRP20201905T1 (hr) 2021-01-22
DK3757107T3 (da) 2023-11-27
LT3352754T (lt) 2021-02-25
MX2021014938A (es) 2022-01-24
IL283809A (en) 2021-07-29
HRP20231563T1 (hr) 2024-03-15
SI3757107T1 (sl) 2024-02-29
EP3352754A4 (en) 2019-04-17
US10150779B2 (en) 2018-12-11
AU2023204218B2 (en) 2025-09-11
US20200283451A1 (en) 2020-09-10
SI3352754T1 (sl) 2021-03-31
PT3352754T (pt) 2020-12-07
JP7688681B2 (ja) 2025-06-04
RU2019101194A (ru) 2020-07-23
IL263631A (en) 2019-01-31
EP3757107A1 (en) 2020-12-30
RU2019101194A3 (enExample) 2020-08-31
US11498925B2 (en) 2022-11-15
JP6895464B2 (ja) 2021-06-30
CN115160339A (zh) 2022-10-11
US10647726B2 (en) 2020-05-12
RS61239B1 (sr) 2021-01-29
BR112018076244A2 (pt) 2019-03-26
CN115160339B (zh) 2024-05-14
US12077547B2 (en) 2024-09-03
US20250163073A1 (en) 2025-05-22
ES2966094T3 (es) 2024-04-18
PL3757107T3 (pl) 2024-03-18
JP2021130719A (ja) 2021-09-09
JP2023171614A (ja) 2023-12-01
US20230312599A1 (en) 2023-10-05
CA3025081A1 (en) 2017-12-28
EP3757107B1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
MX2021014938A (es) Inhibidores de aldosa reductasa y metodos de uso.
HK1217944A1 (zh) 醛糖還原酶抑制劑和其用途
SA522432518B1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة واستخداماتها
TW201613932A (en) Organic compounds
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
WO2016172134A3 (en) Novel compounds
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
MX395534B (es) Inhibidores de demetilasa-1 especifica de lisina.
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
CL2015001536A1 (es) Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras.
MX376047B (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
MX391865B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX385960B (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd).
EA201791070A1 (ru) Способы получения ингибиторов ask1
UY33288A (es) Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
MY188292A (en) Binding proteins specific for lox1 and uses thereof
WO2011133659A3 (en) Inhibitors of hif and angiogenesis
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EP4252755A3 (en) Therapeutic compounds
EA201291346A1 (ru) Полиморфы osi-906

Legal Events

Date Code Title Description
PSEA Patent sealed